GlassScriptPhysician profile
Patrick R Burke
NPI 1215384466
$4,072.71
in general payments reported to CMS, 2019-2025
36 companies · $597 in 2025
The $597 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.09 · 2021: $799 · 2022: $1,859 · 2023: $125 · 2024: $674 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $686.58 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $512.78 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Lilly USA, LLC | $246.86 | 2022-2025 | Emgality, Kisunla |
| Sk Life Science, INC. | $239.24 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $218.84 | 2022 | |
| Genzyme Corporation | $176.84 | 2021-2022 | |
| Ucb, INC. | $148.98 | 2022-2025 | Briviact, Fintepla, Nayzilam |
| Catalyst Pharmaceuticals, INC. | $128.66 | 2022-2025 | Fycompa |
| Amgen INC. | $127.25 | 2022-2024 | Aimovig |
| Biohaven Pharmaceuticals, INC. | $124.67 | 2021 | |
| Genentech USA, INC. | $116.06 | 2022 | |
| Celgene Corporation | $113.57 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $112.82 | 2022 | |
| Amneal Pharmaceuticals LLC | $97.99 | 2021-2022 | |
| Emd Serono, INC. | $95.81 | 2022-2023 | Mavenclad |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $93.29 | 2022 | |
| Lundbeck LLC | $74.15 | 2021-2024 | Vyepti |
| Livanova USA, INC. | $70.45 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $64.60 | 2022-2025 | Ultomiris |
| Supernus Pharmaceuticals, INC. | $63.84 | 2022-2023 | Qelbree |
| Allergan, INC. | $62.22 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $61.21 | 2022 | |
| Biogen, INC. | $59.36 | 2021-2022 | |
| Mdd US Operations, LLC | $55.50 | 2021-2022 | |
| Pfizer INC. | $54.79 | 2022-2025 | |
| Argenx US, INC. | $43.92 | 2022 | |
| Adamas Pharmaceuticals, INC. | $35.18 | 2021 | |
| Mallinckrodt Hospital Products INC. | $33.83 | 2021-2022 | |
| Kyowa Kirin, INC. | $26.89 | 2021 | |
| Neurocrine Biosciences, INC. | $23.54 | 2022 | |
| Neurelis, INC. | $19.93 | 2025 | Valtoco |
| Greenwich Biosciences, INC. | $19.09 | 2019 | |
| Merck Sharp & Dohme LLC | $17.49 | 2022 | |
| Tanabe Pharma America, INC. | $16.85 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.19 | 2022 | |
| Acorda Therapeutics, INC | $13.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Burke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.